A Phase 4 interventional study of Pramipexole SR and Pramipexole IR in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 12 sites in China. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 22nd largest by enrollment, is one of 2 that started in 2018, is one of 10 in phase 4, and was the 24th registered.
4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 40 across 3,358 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 4, and was the 42nd registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the change from baseline to the end of the maintenance period in Parkinson's Disease Sleep Scale 2nd version (PDSS-2) score) in L-dopa+ treated patients with advanced Parkinson's disease (PD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must not have been treated with dopamine agonists within 4 weeks prior to randomization visit. A concomitant treatment with one or more of the following drugs will be allowed (at a stable dose for at least 4 weeks prior to randomization visit and the investigator does not intend to change this treatment during the treatment phase):
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pramipexole SR
Drug: Pramipexole IR
Tablets
Also known as: MIRAPEX®/SIFROL
Tablets
Also known as: MIRAPEX®/SIFROL
Change From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score
Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often). Patients were asked to rate the severity of each question based on their experience during the past week (7 days) from 0 (Never) to 4 (Very often, that meant 6 to 7 days a week). PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance).
Time frame: Baseline and Week 18
Nocturnal Hypokinesia Questionnaire (NHQ) Score (Change From Baseline)
The Nocturnal Hypokinesia Questionnaire (NHQ) is designed to assess hypokinesia symptoms in night in Parkinson's disease (PD) patients, composed of two sections. Section 1 is assessed by PD patients with 10 one-point items evaluating "turning over in bed", "getting out of bed", "parkinsonian motor symptoms", and "others". Section 2 is assessed by spouses or caregivers who are with the patients during the night with 10 one-point items evaluating the same aspects as Section 1. The score for each section is by summing up points from the items in the respective section. Score of each of the two Sections is from 0 to 10, with a higher score indicating worse symptoms. The score was reported by section: Section 1 by patients, Section 2 by caregivers.
Time frame: Baseline and Week 18
Scale for Outcomes in Parkinson's Disease (SCOPA)-Sleep Score (Change From Baseline)
SCOPA-Sleep score is composed of three parts: a night-time scale (5 item scale with 4 Response Options (0-not at all to 3-very much) addressing night time disturbances. Total night-time scale score runs from 0 to 15, with a higher score indicating more severe problems, a single-item about perceived quality of nocturnal sleep (7-point scale ranging from slept very well to slept very badly.), and a daytime sleepiness scale (6 items with 4 Response options, from 0 (never) to 3 (often), and a maximum total score of 18.).
Time frame: Baseline and Week 18
Early Morning Off (EMO) Score (Change From Baseline)
The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").
Time frame: Baseline and Week 18
Responder Rate for Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score<18
Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often) based on their experience during the past week. PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). The PDSS-2 total score less \< 18 were compared between groups.
Time frame: At Week 18
Responder Rate for Early Morning Off (EMO) Score
The responder of EMO is the patient with an improvement of at least 1 comparing to his/her baseline condition. The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").
Time frame: At Week 18
The Parkinson's Disease Questionnaire (PDQ)-8 Score (Change From Baseline)
The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms. The total score summed up the items together and transformed onto a score from 0 (never have problems/issues) to 100 (always have problems or cannot do at all).
Time frame: Baseline and Week 18
Responder Rate for Clinical Global Impression of Improvement (CGI-I)
The responder of CGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The CGI-I was rated (from 1: very much improved, to 7: very much worse) by the same evaluator to assess the overall status of Parkinson's disease.
Time frame: At Week 18
Responder Rate for Patient Global Impression of Improvement (PGI-I)
The responder of PGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The PGI-I scale is a patient-rated instrument (from 1: very much better, to 7: very much worse) which was used to measure the improvement of the patient's Parkinson disease symptoms throughout the study.
Time frame: At Week 18
Epworth Sleepiness Scale (ESS) Score (Change From Baseline)
The ESS is a patient-rated scale about how likely one is to fall asleep during situations of passive and inconsequential to active. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.
Time frame: Baseline and Week 18
This 2-stage open-label, randomised, active controlled parallel group study compared the efficacy and safety of Pramipexole Sustained Release versus Immediate Release administered orally over an 18-week treatment on nocturnal symptoms in patients on Levodopa combined with a Dopa-Decarboxylase-inhibitor with advanced Parkinson's disease.
| Milestone | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Started | 49 | 49 |
| Completed | 45 | 43 |
| Not completed | 4 | 6 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Refused to complete study visit | 1 | 0 |
| Withdrew: Refused to continue trial medication | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Meet exclusion criteria | 0 | 1 |
| Withdrew: Patient not taken study medicine | 0 | 1 |
Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often). Patients were asked to rate the severity of each question based on their experience during the past week (7 days) from 0 (Never) to 4 (Very often, that meant 6 to 7 days a week). PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance).
| Score on a scale | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Change From Baseline to Week 18 in Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score | -13.7 ± 1.16 | -14.4 ± 1.20 |
The Nocturnal Hypokinesia Questionnaire (NHQ) is designed to assess hypokinesia symptoms in night in Parkinson's disease (PD) patients, composed of two sections. Section 1 is assessed by PD patients with 10 one-point items evaluating "turning over in bed", "getting out of bed", "parkinsonian motor symptoms", and "others". Section 2 is assessed by spouses or caregivers who are with the patients during the night with 10 one-point items evaluating the same aspects as Section 1. The score for each section is by summing up points from the items in the respective section. Score of each of the two Sections is from 0 to 10, with a higher score indicating worse symptoms. The score was reported by section: Section 1 by patients, Section 2 by caregivers.
| Score on a scale | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| By patients (Section 1) | -1.9 ± 0.35 | -1.7 ± 0.36 |
| By caregivers (Section 2) | -1.4 ± 0.61 | -0.6 ± 0.67 |
SCOPA-Sleep score is composed of three parts: a night-time scale (5 item scale with 4 Response Options (0-not at all to 3-very much) addressing night time disturbances. Total night-time scale score runs from 0 to 15, with a higher score indicating more severe problems, a single-item about perceived quality of nocturnal sleep (7-point scale ranging from slept very well to slept very badly.), and a daytime sleepiness scale (6 items with 4 Response options, from 0 (never) to 3 (often), and a maximum total score of 18.).
| Score on a scale | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Night-time sleep score | -3.8 ± 0.46 | -3.2 ± 0.47 |
| Overall night sleep score | -1.9 ± 0.20 | -1.6 ± 0.21 |
| Daytime sleepiness score | -1.4 ± 0.34 | -0.9 ± 0.35 |
The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").
| Score on a scale | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Early Morning Off (EMO) Score (Change From Baseline) | -1.8 ± 0.18 | -1.5 ± 0.18 |
Parkinson's disease Sleep Scale 2nd version (PDSS-2) consists of 15 questions about various sleep and nocturnal disturbances which are to be rated by the patients using one of five categories, from 0 (never) to 4 (very often) based on their experience during the past week. PDSS-2 total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). The PDSS-2 total score less \< 18 were compared between groups.
| Percentage of participants | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Responder Rate for Parkinson's Disease Sleep Scale 2nd Version (PDSS-2) Total Score<18 | 73.3 (58.1 to 85.4) | 72.1 (56.3 to 84.7) |
The responder of EMO is the patient with an improvement of at least 1 comparing to his/her baseline condition. The EMO is measured by the question of "do you feel like your bodily movements are poor when you wake up?" Patients answered this question according to the frequency during the previous one week by scoring from 0 ("never") to 4 ("very often" or "6 to 7 days a week").
| Percentage of participants | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Responder Rate for Early Morning Off (EMO) Score | 86.7 (73.2 to 94.9) | 76.7 (61.4 to 88.2) |
The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms. The total score summed up the items together and transformed onto a score from 0 (never have problems/issues) to 100 (always have problems or cannot do at all).
| Score on a scale | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| The Parkinson's Disease Questionnaire (PDQ)-8 Score (Change From Baseline) | -4.1 ± 0.60 | -3.5 ± 0.62 |
The responder of CGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The CGI-I was rated (from 1: very much improved, to 7: very much worse) by the same evaluator to assess the overall status of Parkinson's disease.
| Percentage of participants | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Responder Rate for Clinical Global Impression of Improvement (CGI-I) | 95.6 (84.9 to 99.5) | 86.0 (72.1 to 94.7) |
The responder of PGI-I is the patient rated of any improvement (1 = Very much better, 2 = Much better, or 3 = A little better). The PGI-I scale is a patient-rated instrument (from 1: very much better, to 7: very much worse) which was used to measure the improvement of the patient's Parkinson disease symptoms throughout the study.
| Percentage of participants | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Responder Rate for Patient Global Impression of Improvement (PGI-I) | 95.6 (84.9 to 99.5) | 86.0 (72.1 to 94.7) |
The ESS is a patient-rated scale about how likely one is to fall asleep during situations of passive and inconsequential to active. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness.
| Score on a scale | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Epworth Sleepiness Scale (ESS) Score (Change From Baseline) | -2.4 ± 0.54 | -2.6 ± 0.56 |
Collected over From randomisation through end of treatment until end of follow up visit, up to 18 weeks + 2 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole Sustained Release | 0/49 (0%) | 0/49 (0%) | 4/49 (8.2%) |
| Pramipexole Immediate Release | 0/49 (0%) | 1/49 (2%) | 7/49 (14.3%) |
| Event | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| Mechanical ileusGastrointestinal disorders | 0/49 | 1/49 |
| CholecystitisHepatobiliary disorders | 0/49 | 1/49 |
| CholelithiasisHepatobiliary disorders | 0/49 | 1/49 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/49 | 1/49 |
| Event | Pramipexole Sustained Release | Pramipexole Immediate Release |
|---|---|---|
| DizzinessNervous system disorders | 3/49 | 3/49 |
| DyskinesiaNervous system disorders | 1/49 | 3/49 |
| SomnolenceNervous system disorders | 1/49 | 3/49 |
Treated set (TS) was defined as all patients who were dispensed study medication and were documented to have at least one dose of investigational treatment.
| Age, Continuous(Years) | Pramipexole Sustained Release | Pramipexole Immediate Release | Total |
|---|---|---|---|
| Mean | 61.1 ± 10.80 | 60.9 ± 8.83 | 61.0 ± 9.82 |
| Sex: Female, Male(Participants) | Pramipexole Sustained Release | Pramipexole Immediate Release | Total |
|---|---|---|---|
| Female | 21 | 18 | 39 |
| Male | 28 | 31 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Pramipexole Sustained Release | Pramipexole Immediate Release | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 49 | 49 | 98 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pramipexole Sustained Release | Pramipexole Immediate Release | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 49 | 49 | 98 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Parkinson's disease Sleep Scale 2nd version (PDSS-2) total score(Score on scale) | Pramipexole Sustained Release | Pramipexole Immediate Release | Total |
|---|---|---|---|
| Mean | 27.8 ± 6.45 | 29.2 ± 8.53 | 28.5 ± 7.56 |
| Parkinson's disease Questionnaire (PDQ) -8 score(Score on a scale) | Pramipexole Sustained Release | Pramipexole Immediate Release | Total |
|---|---|---|---|
| Mean | 11.3 ± 4.83 | 10.5 ± 4.99 | 10.9 ± 4.90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Jan 2020, 18 months.
Results were first posted in Feb 2021, 1 year 1 month after primary completion.
Of 57 phase 4 interventional studies under Parkinson Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 65. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole